Half-life
~20–30 hours (vs 12–15 hours native IGF-1)
Evidence Level
Preliminary
Mechanism of Action
Binds IGF-1 receptors. Promotes muscle protein synthesis via mTOR/PI3K/Akt signaling. LR3 modification reduces binding to IGFBPs, increasing free IGF-1 activity.
Published Research Ranges & Study Context
Studies have administered: 20–100mcg/day in research literature
Important Research Framing
These are ranges reported in published scientific studies. They are provided for educational context only and do not constitute dosing recommendations. Individual study parameters vary by design, population, and research objectives. This information is not medical advice.
Primary Research Findings
Studies show superior anabolic effects vs. native IGF-1. Muscle hypertrophy and satellite cell activation demonstrated in animal models.
Preliminary
Primarily preclinical + case reports
Side Effects Observed in Research
Hypoglycemia risk (mitogenic insulin-like activity), water retention, potential mitogenic effects with chronic high-dose use based on receptor activation profiles
Available Configurations (SKU Reference)
IG01
IG1
Compounds Studied in Combination
These compounds have been examined together in research literature. Combination use is not endorsed or recommended — this information is provided for research context only.
Want a Complete Research Monograph?
Our AI can generate a 2,000+ word deep-dive on IGF-1 LR3 — including full clinical trial summaries, pharmacokinetics, and research frontiers.
Generate Deep Dive in Research Chat
Research Education Only: This compound profile is for educational purposes only. All information is sourced from published scientific literature. This is not medical advice. Not for human consumption. Consult qualified medical professionals for any health decisions. Regulatory status varies by jurisdiction.